ALID (Allied) YoY EBITDA Growth: 16.67% (As of Nov. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Allied YoY EBITDA Growth?

Allied ALID -99.80% YoY EBITDA Growth is 16.67% as of Nov. 2024.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Allied's YoY EBITDA Growth for the quarter that ended in Nov. 2024 was 16.67%.

Allied's EBITDA per Share for the three months ended in Nov. 2024 was $-0.01.

Allied YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Allied's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allied YoY EBITDA Growth Chart

Allied Annual Data
Trend Mar18 Mar19 Aug20 Aug21 Aug22 Aug23 Aug24
YoY EBITDA Growth
Get a 7-Day Free Trial 0.00 -62.16 -28.33 35.06 72.00

Allied Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.45 68.42 70.00 80.00 16.67

Allied YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Allied's YoY EBITDA Growth for the fiscal year that ended in Aug. 2024 is calculated as:

YoY EBITDA Growth (A: Aug. 2024 )
=(EBITDA per Share (A: Aug. 2024 )-EBITDA per Share (A: Aug. 2023 ))/ | EBITDA per Share (A: Aug. 2023 ) |
=(-0.028--0.1)/ | -0.1 |
=72.00 %

Allied's YoY EBITDA Growth for the quarter that ended in Nov. 2024 is calculated as:

YoY EBITDA Growth (Q: Nov. 2024 )
=(EBITDA per Share (Q: Nov. 2024 )-EBITDA per Share (Q: Nov. 2023 )) / | EBITDA per Share (Q: Nov. 2023 )) |
=(-0.005--0.006)/ | -0.006 |
=16.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 16.67% mean?
Allied (ALID) has a YoY EBITDA Growth of 16.67% as of Nov. 2024. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Allied and its competitors.
Is Allied's YoY EBITDA Growth too high?
Allied's current YoY EBITDA Growth is 16.67%.
How does Allied's YoY EBITDA Growth compare to CBDY and PLSH?
Allied's YoY EBITDA Growth of 16.67% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Drug Manufacturers company?
A good YoY EBITDA Growth depends on the Drug Manufacturers industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Allied and its competitors. Allied's current YoY EBITDA Growth is 16.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allied stock overvalued right now?
Allied (ALID) has a current YoY EBITDA Growth of 16.67%. The current YoY EBITDA Growth is 16.67%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Allied (ALID), the current YoY EBITDA Growth is 16.67% as of Nov. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allied Business Description

Address 460 Doyle Avenue, Suite 200, Kelowna, BC, CAN, V1Y OC2
Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments, which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised of sales of cannabis products.